Research & Development: Page 2
-
Stock via Getty Images
Women want to participate in clinical trials. Lack of flexibility is still a problem.
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line, but even small changes can fuel participation.
By Kelly Bilodeau • April 8, 2024 -
Stock via Getty Images
Viral return: 3 U.S. cases concerning experts
Infectious diseases that were “off the playing field” are now making a comeback.
By Meagan Parrish • April 5, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineEmerging biotech
After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff -
Permission granted by Verastem
Q&A // First 90 DaysWith an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
By Michael Gibney • April 4, 2024 -
Stock via Getty Images
As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
By Amy Baxter • April 3, 2024 -
Getty Images via Getty Images
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
By Michael Gibney • April 2, 2024 -
Scott Olson/Staff via Getty Images
With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care
Eledon Pharmaceuticals is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
By Kelly Bilodeau • April 1, 2024 -
Permission granted by Rivus Pharmaceuticals
To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach
Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.
By Amy Baxter • March 29, 2024 -
Permission granted by Cardior
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.
By Michael Gibney • March 28, 2024 -
Stock via Getty Images
Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS
Ahead of more guidance from the FDA on diversity in clinical trials, Takeda is aiming to beat industry standards.
By Amy Baxter • March 27, 2024 -
Permission granted by Portal Bio
Q&ASQZ, Portal founder Armon Sharei on starting over in biotech
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
By Gwendolyn Wu • March 26, 2024 -
Permission granted by Gates MRI
ProfileThe pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle
After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.
By Alexandra Pecci • March 22, 2024 -
Permission granted by Wyss Institute
Q&AAn ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
By Michael Gibney • March 21, 2024 -
Courtesy of Madrigal
With historic MASH approval, Madrigal preps for launch and a public offering
After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.
By Amy Baxter • March 20, 2024 -
Stock via Getty Images
Q&A // Biotech SpotlightGSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
By Alexandra Pecci • March 19, 2024 -
Getty Images via Getty Images
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
By Michael Gibney • March 19, 2024 -
Stock via Getty Images
After Amylyx drug failure, what’s next for ALS?
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
By Meagan Parrish • March 15, 2024 -
Alex Wong/Getty Images via Getty Images
Q&AFormer U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
By Michael Gibney • March 14, 2024 -
Stock via Getty Images
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
By Alexandra Pecci • March 12, 2024 -
Stock via Getty Images
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Stock via Getty Images
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
By Kelly Bilodeau • March 11, 2024 -
Permission granted by Tarsus Pharmaceuticals
Q&AInto the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
By Meagan Parrish • March 8, 2024 -
Mario Tama via Getty Images
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.
By Michael Gibney • March 7, 2024 -
Stock via Getty Images
Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
By Kelly Bilodeau • March 6, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
Permission granted by Nasdaq, Inc.
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead.
By Gwendolyn Wu , Ben Fidler • March 5, 2024
Previous
